Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study

Suzuki, Kensuke; Furuse, Hideaki; Tsuda, Takeshi; Masaki, Yasuaki; Okazawa, Seisuke; Kambara, Kenta; Inomata, Minehiko; Miwa, Takeshi; Matsui, Shoko; Kashii, Tatsuhiko; Taniguchi, Hirokazu; Hayashi, Ryuji; Tobe, Kazuyuki

doi:10.1177/0300060515579116

Cited by 38 publications

(28 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported that the sarcopenia index could predict in-hospital mortality and 90-day mortality in ICU patients 12 . Another recent study found that the creatinine/cystatin C ratio could predict the toxicity of chemotherapy in patients with non-small cell lung cancer 19 . Moreover, Tsuneda et al .…”

Section: Discussionmentioning

confidence: 99%

A sarcopenia index based on serum creatinine and cystatin C cannot accurately detect either low muscle mass or sarcopenia in urban community-dwelling older people

Jiang

Xie

Zhang³

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to evaluate the diagnostic value of the sarcopenia index (serum creatinine [mg/dl]/cystatin C [mg/dl] × 100) for estimating low muscle mass and sarcopenia in community-dwelling older adults. We included 371 older adults (≥60 years) with normal kidney function. Four common diagnostic criteria (the European Working Group on Sarcopenia in Older People (EWGSOP), Asia Working Group for Sarcopenia (AWGS), International Working Group on Sarcopenia (IWGS), and Foundation for the National Institutes of Health (FNIH) criteria) were separately applied as the “gold standard”. The receiver operating characteristic (ROC) curves and the area under the ROC curves (AUC) were applied to evaluate the overall diagnostic accuracy. For identifying low muscle mass, the AUC ranged from 0.505 (95% confidence interval [CI] 0.453–0.557) to 0.558 (95% CI 0.506–0.609). For identifying sarcopenia, the AUC ranged from 0.555 (95% CI 0.503–0.606) to 0.618 (95% CI 0.566–0.668). Subgroup analyses according to gender showed similar results. In conclusion, the sarcopenia index based on serum creatinine and cystatin C may not serve as biomarkers of either low muscle mass or sarcopenia in urban community-dwelling older people with normal kidney function.

show abstract

Section: Discussionmentioning

confidence: 99%

A sarcopenia index based on serum creatinine and cystatin C cannot accurately detect either low muscle mass or sarcopenia in urban community-dwelling older people

Jiang

Xie

Zhang³

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Based on the aforementioned characteristics of Scre and Scys, we postulate that the Scre/Scys ratio can be used as a surrogate for skeletal muscle mass and hepatic function in chronic liver disease patients with cirrhosis or HCC. Although a low Scre/Scys ratio was linked with poor chemotherapy tolerability in lung cancer patients, there exist no data on the association of Scre/Scys ratio with muscle mass assessed by body composition analysis, or with the survival rate of liver disease patients with HCC.…”

Section: Introductionmentioning

confidence: 99%

Ratio between estimated glomerular filtration rates of creatinine and cystatin C predicts overall survival in patients with hepatocellular carcinoma

Tamai

Iwasa

Kawasaki

et al. 2018

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Moreover, the serum creatinine/cystatin C ratio has been applied for other purposes in different populations. For example, in a retrospective study, Suzuki et al 29 reported that serum creatinine/cystatin C ratio appeared to be a predictive marker for chemotherapy-related adverse effects in patients with lung cancer. In another multicenter prospective study, Komorita et al 30 applied serum creatinine/cystatin C ratio in patients with type 2 diabetes and regularly attending teaching hospitals or diabetes clinics.…”

Section: Discussionmentioning

confidence: 99%

Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients

Tang

Zhuo

Xie

et al. 2020

Sci Rep

View full text Add to dashboard Cite

To investigate the association of the sarcopenia index (SI, serum creatinine value/cystatin C value × 100) with 3-year mortality and readmission among older inpatients, we reanalyzed a prospective study in the geriatric ward of a teaching hospital in western China. Older inpatients aged ≥ 60 years with normal kidney function were included. Survival status and readmission information were assessed annually during the 3-year follow-up. We applied Cox regression models to calculate the hazard ratio (HR) and 95% confidence intervals (CIs) of sarcopenia for predicting mortality and readmission. We included 248 participants (mean age: 81.2 ± 6.6 years). During the follow-up, 57 participants (23.9%) died, whereas 179 participants (75.2%) were readmitted at least one time. The SI was positively correlated with body mass index (BMI) (r = 0.214, p = 0.001), calf circumference (CC) (r = 0.253, p < 0.001), handgrip strength (r = 0.244, p < 0.001), and gait speed (r = 0.221, p < 0.001). A higher SI was independently associated with a lower risk of 3-year all-cause mortality after adjusting for potential confounders (HR per 1-SD = 0.80, 95% CI: 0.63-0.97). The SI was not significantly associated with readmission (HR per 1-SD = 0.97, 95% CI: 0.77-1.25). In conclusion, the SI is associated with 3-year all-cause mortality but not readmission in a study population of hospitalized older patients.

show abstract

Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study

Abstract: The Cr/CysC ratio could serve as a useful predictive marker for chemotherapy-related adverse effects in patients with NSCLC.

Cited by 38 publications

References 37 publications

A sarcopenia index based on serum creatinine and cystatin C cannot accurately detect either low muscle mass or sarcopenia in urban community-dwelling older people

A sarcopenia index based on serum creatinine and cystatin C cannot accurately detect either low muscle mass or sarcopenia in urban community-dwelling older people

Ratio between estimated glomerular filtration rates of creatinine and cystatin C predicts overall survival in patients with hepatocellular carcinoma

Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients

Contact Info

Product

Resources

About